TBPH insider trading
NasdaqGM HealthcareTheravance Biopharma, Inc.: insider trade history from SEC Form 4 filings.
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Company website: www.theravance.com
TBPH insider activity at a glance
FilingIQ tracks 680 insider transactions for TBPH in filings since Feb 9, 2015. The most recent transaction is dated Sep 23, 2026.
Across the full history, 17 open-market purchases
and 80 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on TBPH insider trades is 56.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest TBPH Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for TBPH?
- FilingIQ tracks 680 Form 4 insider transactions for TBPH (Theravance Biopharma, Inc.), covering filings from Feb 9, 2015 onwards. 34 of those are dated within the last 90 days.
- Are TBPH insiders net buyers or net sellers?
- Across the full Form 4 history for TBPH, 17 transactions (3%) were open-market purchases and 80 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TBPH insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is TBPH in?
- Theravance Biopharma, Inc. (TBPH) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $978.01M.
Methodology & sources
Every TBPH insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.